- Home
- SFM vs PRAX Comparison
SFM vs PRAX Comparison
Compare SFM & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SFM | PRAX |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 7.2B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SFM | PRAX |
|---|---|---|
| Price | $80.97 | $280.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $138.64 | ★ $374.64 |
| AVG Volume (30 Days) | ★ 2.3M | 580.3K |
| Earning Date | 02-19-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.03 | N/A |
| EPS | ★ 5.15 | N/A |
| Revenue | ★ $8,653,696,000.00 | $7,463,000.00 |
| Revenue This Year | $15.28 | N/A |
| Revenue Next Year | $9.87 | $12,467.71 |
| P/E Ratio | $15.58 | ★ N/A |
| Revenue Growth | 16.60 | ★ 364.98 |
| 52 Week Low | $74.38 | $26.70 |
| 52 Week High | $182.00 | $317.72 |
Technical Indicators
Market Signals| Indicator | SFM | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 56.56 |
| Support Level | $74.38 | $266.93 |
| Resistance Level | $81.53 | $305.21 |
| Average True Range (ATR) | 2.47 | 14.88 |
| MACD | 0.39 | -4.29 |
| Stochastic Oscillator | 92.17 | 27.40 |
Price Performance
Historical ComparisonAbout SFM Sprouts Farmers Market Inc.
Sprouts Farmers Market Inc offers a specialty grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspire wellness naturally with a carefully curated assortment products paired with purpose-driven people. The company continues to bring products made with lifestyle-friendly ingredients such as organic, plant-based, and gluten-free. It approximately has 407 stores in nearly 23 states. The Company has one operating segment that is healthy grocery stores.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.